万健投资拟于本减持计划公告之日起15个交易日后的3个月内，通过集中竞 价、大宗交易方式减持公司股份不超过5,135,668股，拟减持比例不超过公司总 股本的3%。其中在任意连续90日内通过集中竞价交易方式减持数量不超过 1,711,889股，即不超过公司总股本的1%；在任意连续90日内通过大宗交易方式 减持数量不超过3,423,779股，即不超过公司总股本的2%。减持价格视市场价格 确定。若此期间公司有派息、送股、资本公积金转增股本、配股等除权除息事项 的，减持股份数、股权比例将相应进行调整。 证券代码：603079 证券简称：圣达生物 公告编号：2024-063 浙江圣达生物药业股份有限公司股东减持股份计划 公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东持股的基本情况 浙江圣达生物药业股份有限公司（以下简称"公司"）5%以上大股东天台万 健投资发展中心（有限合伙）（以下简称"万健投资"）持有公司股份32,771,141 股，占公司总股本的19.14%。万健投资的一致行动人浙江圣达集团有 ...

Investment Rating - The report does not explicitly state an investment rating for the company [1]. Core Insights - The company's main products include vitamin products and biological preservatives, with a focus on biotin and folic acid, which are used in various industries such as feed additives, food additives, and pharmaceuticals [1][21]. - The company has seen a significant increase in sales of folic acid, with a year-on-year growth of 69.10% in sales volume and 77.24% in sales revenue [2][21]. - The price of folic acid has surged by 87.5% since November 1, 2024, reaching RMB 330 per kg, which is expected to enhance the company's profitability [4][17]. - The company plans to raise funds through a stock issuance to increase the production capacity of D-isoascorbic acid and its sodium salt, which has a total demand exceeding 200,000 tons [3][16]. Summary by Sections Company Overview - The company primarily produces vitamin products, biological preservatives, and clean label products, with biotin and folic acid being key offerings [1][21]. - In the first three quarters of 2024, the company achieved operating income of RMB 609 million, a year-on-year increase of 11.90% [1][21]. Sales Performance - In 2023, biological preservatives generated sales of RMB 305 million, accounting for 41.89% of total revenue, while vitamin sales were RMB 248 million, representing a decline of 18.96% [2][8]. - Clean label products saw a significant increase in sales, reaching RMB 65 million, a growth of 48.27% year-on-year [2][21]. Market Position - The company is the largest global supplier of biotin with a market share of approximately 30% and has a growing market share of 26% in folic acid [4][17]. - The biological preservatives market is primarily driven by lactic acid streptococcus and natamycin, with the company being a leading manufacturer in this segment [4][18]. Future Prospects - The planned stock issuance aims to fund the expansion of D-isoascorbic acid production, which is expected to create new growth opportunities for the company [3][16]. - The demand for D-isoascorbic acid has expanded significantly, with domestic demand increasing 60 times since 1996, indicating a robust market potential [3][16].

证券代码：603079 证券简称：圣达生物 公告编号：2024-062 浙江圣达生物药业股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 股票交易异常波动的具体情况 公司股票于2024年11月25日、11月26日、11月27日连续三个交易日内日收盘 价格跌幅偏离值累计超过20%，根据《上海证券交易所交易规则》的有关规定， 属于股票交易异常波动情形。 二、 公司关注并核实的相关情况 （一）生产经营情况 三、 相关风险提示 经公司自查，公司日常经营活动正常，市场环境、行业政策没有发生重大调 整，内部生产经营秩序正常，不存在应披露而未披露的重大信息。 （二）重大事项情况 经公司自查，并书面征询公司控股股东浙江圣达集团有限公司和实际控制人 浙江圣达生物药业股份有限公司（以下简称"公司"）股票于2024年11月25 日、11月26日、11月27日连续三个交易日内日收盘价格跌幅偏离值累计超过 20%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波 动情形。 经公司自查， ...

关于《浙江圣达生物药业股份有限公司股票交易异常波动问询函》的 回复 浙江圣达生物药业股份有限公司： 贵公司发来的《浙江圣达生物药业股份有限公司股票交易异常波动问询函》 已收悉，经本集团自查，现回复如下： 关于《浙江圣达生物药业股份有限公司股票交易异常波动问询函》的 回复 浙江圣达生物药业股份有限公司： 贵公司发来的《浙江圣达生物药业股份有限公司股票交易异常波动问询函》 已收悉，经本人自查，现回复如下： 本人作为贵公司的实际控制人，截至目前，不存在影响上市公司股票异常波 动的重大事项，不存在其他应披露而未披露的重大信息，包括但不限于筹划涉及 上市公司的重大资产重组、股份发行、重大交易类事项、收购、债务重组、业务 重组、资产剥离、资产注入、股份回购、股权激励、破产重整、重大业务合作、 引进战略投资者等重大事项。 本集团作为贵公司的控股股东，截至目前，不存在影响上市公司股票异常波 动的重大事项，不存在其他应披露而未披露的重大信息，包括但不限于筹划涉及 上市公司的重大资产重组、股份发行、重大交易类事项、收购、债务重组、业务 重组、资产剥离、资产注入、股份回购、股权激励、破产重整、重大业务合作、 引进战略投资者等重大事 ...

证券代码：603079 证券简称：圣达生物 公告编号：2024-061 浙江圣达生物药业股份有限公司董事会 2024年11月23日 浙江圣达生物药业股份有限公司 公司本次向特定对象发行股票事项尚需中国证券监督管理委员会（以下简 称"中国证监会"）作出同意注册决定后方可实施，最终能否获得中国证监会 同意注册的决定及其时间尚存在不确定性。公司将根据该事项的进展情况及时 履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 上海证券交易所上市审核中心审核通过的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 关于申请向特定对象发行股票获得 浙江圣达生物药业股份有限公司（以下简称"公司"）于近日收到上海证 券交易所上市审核中心《关于浙江圣达生物药业股份有限公司向特定对象发行 股票审核意见的通知》。根据审核结果，公司向特定对象发行股票申请符合发 行条件、上市条件和信息披露要求。 ...

Group 1 - The core viewpoint is that Shengda Bio has experienced significant stock performance, achieving a limit-up on multiple trading days [1] - Over the past five trading days, the stock has recorded three limit-up days, resulting in a cumulative increase of 31.17% [1] - The cumulative turnover rate for the stock during this period is 60.38% [1] Group 2 - As of 10:31, the trading volume for the stock today is 23.92 million shares, with a transaction amount of 472 million yuan [1] - The turnover rate for the stock today is 13.98% [1] - The total market capitalization of A-shares has reached 3.494 billion yuan [1]

证券代码：603079 证券简称：圣达生物 公告编号：2024-060 浙江圣达生物药业股份有限公司 一、报告期内主要产品的产量、销量及收入实现情况 主要产品 产量（吨） 销售（吨） 营业收入（万元） 维生素 137.47 163.05 6,217.51 生物保鲜剂 414.76 412.55 8,564.69 单位：万元 主要产品 营业收入 （境内） 较上年同期 增减（%） 营业收入 （境外） 较上年同期 增减（%） 维生素 2,510.34 41.10 3,707.17 -6.65 生物保鲜剂 6,259.49 -7.62 2,305.20 7.50 2024年第三季度主要经营数据公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上市公司自律监管指引第3号行业信息披露：第十三 号——化工》（2022年修订）及《上市公司自律监管指引第3号行业信息披露： 第十四号——食品制造》（2022年修订）的要求，现将浙江圣达生物药业股份 有限公司（以下简称"公司"）2024年第三季度主要经营数据披露如下： 注：公 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥224,395,495.23, representing a year-on-year increase of 23.92%[2] - The net profit attributable to shareholders for Q3 2024 was ¥5,184,192.38, a significant increase of 95.99% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached ¥4,462,407.04, reflecting a remarkable growth of 557.91% year-on-year[2] - The basic earnings per share for Q3 2024 was ¥0.03, an increase of 50.00% compared to the same period last year[4] - The diluted earnings per share for Q3 2024 was also ¥0.03, marking a 50.00% increase year-on-year[4] - Total operating revenue for the first three quarters of 2024 reached CNY 608,870,278.32, an increase of 11.9% compared to CNY 544,108,238.57 in the same period of 2023[20] - Net profit for the first three quarters of 2024 was CNY 27,409,202.51, a significant recovery from a net loss of CNY 2,626,697.31 in the same period of 2023[20] - The company reported a basic and diluted earnings per share of CNY 0.13 for the first three quarters of 2024, compared to a loss of CNY 0.02 in the same period of 2023[22] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥81,273,978.16, showing a substantial increase of 429.00% compared to the previous year[2] - The net cash flow from operating activities increased to ¥81,273,978.16, compared to ¥15,363,815.47 in the previous year, reflecting a significant improvement[23] - Cash inflow from operating activities totaled ¥630,322,252.29, up from ¥591,147,959.53 year-over-year[23] - Cash outflow from operating activities decreased to ¥549,048,274.13 from ¥575,784,144.06, indicating better cost management[23] - The net cash flow from investing activities was -¥215,604,257.27, worsening from -¥149,919,673.60 in the previous year, primarily due to increased investment expenditures[24] - Cash inflow from investing activities rose to ¥108,199,568.08, compared to ¥23,575,218.34 in the previous year, driven by higher cash recovered from investments[24] - Cash outflow from investing activities increased to ¥323,803,825.35 from ¥173,494,891.94, reflecting a strategic push in capital expenditures[24] - The net cash flow from financing activities was -¥28,408,400.53, a decline from ¥129,183,362.70 in the previous year, indicating reduced financing activities[24] - Cash inflow from financing activities decreased to ¥132,000,000.00 from ¥178,000,000.00, showing a reduction in borrowing[24] - The ending cash and cash equivalents balance was ¥145,548,823.61, down from ¥300,424,462.60, highlighting liquidity challenges[24] - The company reported a significant increase in cash received from investment recoveries, amounting to ¥105,000,000.00, compared to ¥22,000,000.00 in the previous year[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,739,660,936.95, reflecting a slight increase of 1.19% from the end of the previous year[4] - As of September 30, 2024, total current assets amounted to RMB 666,883,511.03, a decrease from RMB 695,148,552.16 as of December 31, 2023[16] - The company's total assets reached RMB 1,739,660,936.95, compared to RMB 1,719,185,557.88 at the end of 2023, indicating a slight increase[17] - Long-term borrowings increased to RMB 210,000,000.00 from RMB 144,000,000.00, reflecting a significant rise in non-current liabilities[17] - The company’s total liabilities decreased to RMB 239,899,213.71 from RMB 295,454,343.18, indicating improved financial leverage[17] - The total liabilities increased to CNY 465,535,062.96 from CNY 449,195,537.01, marking a rise of 3.0%[20] - The total equity attributable to shareholders of the parent company was CNY 1,253,086,190.35, a slight decrease from CNY 1,254,680,511.87[20] Shareholder Information - The company reported a total of 18,323 common shareholders at the end of the reporting period[9] - Zhejiang Shengda Group Co., Ltd. held 26.51% of the shares, with 10,400,000 shares pledged[9] - The top 10 shareholders include Zhejiang Shengda Group Co., Ltd. with 45,375,792 shares and Tian Tai Wan Jian Investment Development Center with 32,771,141 shares[11] - The company has not reported any changes in the participation of its top shareholders in margin financing and securities lending activities[12] - The actual controller of the company is Hong Ai, who is also the spouse of Zhu Yonggang, a significant shareholder[11] - The company has not disclosed any related party transactions or agreements among its shareholders beyond those mentioned[11] Investment and Fundraising - The company plans to issue up to 51,356,687 A-shares to specific investors, aiming to raise a total of no more than 500 million RMB for production projects[13] - The adjusted total amount for the fundraising has been revised from 500 million RMB to 267.61 million RMB[13] - The company is investing in the production of 3 billion soft capsules and 3 billion solid preparations, along with a project for an annual output of 20,000 tons of D-isoascorbic acid and its sodium salt[13] - The company received an inquiry letter from the Shanghai Stock Exchange regarding its stock issuance application, with responses provided on multiple occasions[13] - The company has not engaged in any share buyback activities during the reporting period[13] - The company completed a share repurchase plan, acquiring 1,872,500 shares, representing 1.09% of total equity, at an average price of RMB 11.79 per share, totaling RMB 22,078,434.00[14] - The company plans to implement an employee stock ownership plan, with a maximum of 872,500 shares to be held, funded by a total of RMB 499.95 million[14] Research and Development - Research and development expenses amounted to CNY 29,025,818.97, slightly down from CNY 30,185,572.78 in the previous year[20] Tax and Investment Income - The company recorded an investment income of CNY 3,015,295.08, compared to CNY 735,390.44 in the previous year, indicating a positive trend[20] - Deferred income tax liabilities decreased to CNY 3,047,545.31 from CNY 4,276,770.45, showing a reduction of 28.7%[20]

浙江圣达生物药业股份有限公司 2024 年员工持股计划 证券简称：圣达生物 证券代码：603079 浙江圣达生物药业股份有限公司 2024 年员工持股计划 二〇二四年九月 1 浙江圣达生物药业股份有限公司 2024 年员工持股计划 声明 本公司及全体董事、监事保证本员工持股计划及其摘要不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 本方案主要条款与公司 2024 年 8 月 23 日公告的本员工持股计划草案及 其摘要内容一致。 四、本员工持股计划中有关公司业绩考核指标的描述不代表公司的业绩 预测，亦不构成业绩承诺。 五、敬请广大投资者谨慎决策，注意投资风险。 3 浙江圣达生物药业股份有限公司 2024 年员工持股计划 特别提示 2 浙江圣达生物药业股份有限公司 2024 年员工持股计划 风险提示 一、浙江圣达生物药业股份有限公司（以下简称"圣达生物""公司" 或"本公司"）2024 年员工持股计划（以下简称"本员工持股计划"）的具 体的资金来源、出资金额、预计规模和具体实施方案等属初步结果，能否完 成实施，存在不确定性。 二、若员工认购资金较低，本员工持股计划 ...

浙江天册律师事务所 关于 浙江圣达生物药业股份有限公司 2024 年第二次临时股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼邮编 310007 电话：0571 8790 111 传真：0571 8790 1500 https://www.tclawfirm.com/ 法律意见书 浙江天册律师事务所 关于浙江圣达生物药业股份有限公司 2024 年第二次临时股东大会的 法律意见书 编号：TCYJS2024H1525 号 致：浙江圣达生物药业股份有限公司 浙江天册律师事务所（以下简称"本所"）接受浙江圣达生物药业股份有限公 司（以下简称"圣达生物"或"公司"）的委托，指派本所律师参加公司 2024 年第 二次临时股东大会（以下简称"本次股东大会"），并根据《中华人民共和国证券 法》（以下简称"《证券法》"）、《中华人民共和国公司法》（以下简称"《公 司法》"）和《上市公司股东大会规则（2022 年修订）》（以下简称"《股东大会 规则》"）等有关法律、行政法规、规章和其他规范性文件的要求以及《浙江圣达 生物药业股份有限公司章程》（以下简称"《公司章程》"）的规定，出具本法律 意见书。 ...